Novartis skin-cancer drug meets main goal in Phase II trial


Novartis' (NVS) Sonidegib treatment met its primary goal of achieving a "clinically significant tumor response" in a Phase II trial of patients with Basal cell carcinoma, the most common form of skin cancer.

In some patients, tumors disappeared completely within six months of treatment and in others they shrank significantly.

Novartis intends to present the full results of the study at a future scientific meeting.

Meanwhile, Japanese prosecutors have raided Novartis' Tokyo office as part of a criminal probe into whether the company violated regulations by exaggerating the effectiveness of its Diovan hypertension drug in marketing materials.

Officers took documents that they want to look at as part of the investigation.

The alleged breach could lead to fines of up to ¥2M ($19,500) and jail terms of two years.

From other sites
Comments (1)
  • daisymae
    , contributor
    Comments (17) | Send Message
     
    My dad wouldn't even buy fugi film let alone listen to the Japanese accuse $NVS of any wrong doing....He was ACE night fighter pilot in WW11with the painting on the sides of his plane spelling out the words "Battle AX"....(his name was E. Axtell) only one to survive his squadron. Even the Air Force could not find enough spare parts to re-build P-61 (I'm pretty sure that was the #) to display it at the RED STONE ARSONAL Museum in Huntsville Alabama where he worked after WWW11 was over. Somehow had a grudge against those enemies at the time.
    19 Feb 2014, 01:24 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs